retatrutide parkinson's disease trial nct Randomized Trial of Focused Ultrasound Subthalamotomy for Parkinson's Disease Retatrutide produces up to 30.3%
Description
Richard Daikeler, Gtz Use, Sylke Waibel: Diabetes
Brand-name Wegovy and Zepbound are sometimes covered for patients with documented obesity (BMI 30+) or BMI 27+ with a comorbid condition
Contact us to learn how Aons analytics capabilities helps organizations make better workforce decisions
It is a metabolic strategy with measurable outcomes
The physician stated she did agree the initial 27 BMI level used by the state for GLP-1 coverage was too low, stating resources are limited
